Neuroblastoma is a rare, but deadly childhood cancer. Only 1 patient per 100.000 children, under the age of 15, are diagnosed with neuroblastoma per year. Due to a very heterogeneous genetic background, patients show a very different progression of the disease. To increase survival, we shifted our focus to the non-coding genome of this cancer, to identify new specific targets for therapy. Currently, the therapeutic strategy that is been deployed is antisense technology, to knock the potential targets of interest down.
I obtained a Master of Science: Bioscience engineering (UGent, 2013). Currently, I am a full time doctoral fellow (previously: IWT fellowship, now: KOTK Emmanuel van der Schueren grant) at UGent.